Ensuring that injectable bicarbonate-buffered lidocaine-epinephrine complies with 2015 United States Pharmacopeia (USP) compounding provisions - 20/07/16
Doi : 10.1016/j.jaad.2016.03.051
Prescilia Isedeh, MD a, M. Laird Forrest, PhD b, Deede Liu, MD a, Daniel Aires, MD, JD a, ⁎ 
a Division of Dermatology, University of Kansas Medical Center, Kansas City, Kansas
b Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas
∗Reprint requests: Daniel Aires, MD, JD, Division of Dermatology, University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS 66103.Division of DermatologyUniversity of Kansas Medical Center3901 Rainbow BlvdKansas CityKS66103
Key words : bicarbonate-buffered lidocaine-epinephrine, compounded sterile preparations, International Organization for Standardization class, microbial risk, United States Pharmacopeia
Le texte complet de cet article est disponible en PDF.
| This piece received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Dr Forrest's efforts were funded in part by National Institutes of Health grants NCI 1R01CA173292 and FDA 1U01FD005285. |
|
| Conflicts of interest: None declared. |
© 2016
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 75 - N° 2
P. 454-455 - août 2016 Retour au numéro
Article précédent
- Early-onset stroke, polyarteritis nodosa (PAN), and livedo racemosa
- Dominique C. Pichard, Amanda K. Ombrello, Patrycja Hoffmann, Deborah L. Stone, Edward W. Cowen
- Correction
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?